

1-22-02

A

PTO/SB/05 (03-01)

Please type a plus sign (+) inside this box → ☒

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	103576.504
First Inventor	Zhijian J. Chen
Title	Kinase Capable of Site-Specific . . .
Express Mail Label No.	EV038245590US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

**ADDRESS TO:** Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

1. ☒ Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2. ☐ Applicant claims small entity status.  
See 37 CFR 1.27.
3. ☒ Specification [Total Pages **120**]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets **32**]
5. Oath or Declaration [Total Pages **2**]
  - a. ☐ Newly executed (original or copy)  
Copy from a prior application (37 CFR 1.63 (d))
  - b. ☒ (for continuation/divisional with Box 18 completed)
    - i. ☐ **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6. ☒ Application Data Sheet. See 37 CFR 1.76

7. ☐ CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a. ☒ Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i. ☐ CD-ROM or CD-R (2 copies); or
    - ii. ☒ paper
  - c. ☒ Statements verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

9. ☒ Assignment Papers (cover sheets & documents)
10. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☒ Power of Attorney
11. ☐ English Translation Document (if applicable)
12. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☐ Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17. ☐ Other: .....

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

☒ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)of prior application No.: **09 / 406,293**

Prior application information:

Examiner **C. Patterson**Group Art Unit: **1652**

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**19. CORRESPONDENCE ADDRESS**☒ Customer Number or Bar Code Labelor ☐ Correspondence address below

Name

**23483**

PATENT TRADEMARK OFFICE

Address

City

State

Zip Code

Country

Telephone

Fax

Name (Print/Type)

Janice M. Klunder, Ph.D.

Registration No. (Attorney/Agent)

41,121

Signature

Date

01/17/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

EXPRESS MAIL LABEL NO. EV038245590 US  
DATE OF DEPOSIT 1/17/02

PATENTS  
Attorney Docket Number 103576.504



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Zhijian J. Chen

Art Unit: To be assigned

Serial No.: To be assigned

Examiner: To be assigned

Filing Date: Herewith

Title: Kinase Capable of Site-Specific  
Phosphorylation of IκBα

Box Patent Application  
Commissioner for Patents  
Washington, DC 20231

**REQUEST TO USE COMPUTER READABLE FORM FROM ANOTHER  
PATENT APPLICATION UNDER 37 C.F.R. § 1.821(e)**

Dear Commissioner for Patents:

Pursuant to 37 C.F.R. 1.125, the continuation application filed herewith is being filed with a substitute specification. The specification filed herewith differs from the parent application in containing a new claim set, updated priority information, amended abstract, and corrected drawings. No new matter has been added by way of these changes.


The computer readable Sequence Listing in the application filed herewith is identical with that filed in Application Number 08/825,559, filed on March 19, 1997, now U.S. Patent No. 6,107,073. In accordance with 37 C.F.R. § 1.821(e), please use the only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the instant application.

In accordance with 37 C.F.R. § 1.821(f), I hereby state that the paper copy of the Sequence Listing submitted herewith in the instant application is the same as the computer readable Sequence Listing filed in Application Number 08/825,559.

No fees other than those provided for in the papers enclosed herewith are believed to be due in connection with this communication. However, pursuant to 37 C.F.R. § 1.136(a)(3), the Examiner is authorized to charge any fee under 37 C.F.R. § 1.17 applicable in the instant, as well as in future communications, to Deposit Account No. 08-0219. Such an authorization should be treated as a constructive petition for extension of time in the concurrent as well as future communications in the above-identified application.

Please also charge any payments due or credit any overpayments associated with this matter to our Deposit Account No. 08-0219.

Respectfully submitted,



Janice M. Klunder, Ph.D.  
Reg. No. 41,121

January 17, 2002

HALE AND DORR LLP  
60 State Street  
Boston, MA 02109  
Tel: (617) 526-6771  
Fax: (617) 526-5000